Stocks & ETFs Screener: 200+ results (Biotechnology)
| Symbol | Industry | Market Cap | Fund. Score | Div. Score | Tech. Score | P/E | Return 12m vs S&P 500 |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie |
Biotechnology
Medicine, Therapy, Cancer |
370B | 60.9% | 73.0% | 71.8% | 99.8 | -6.34% |
| NOVO-B Novo Nordisk |
Biotechnology
Diabetes, Obesity, Insulin |
240B | 77.1% | 63.6% | 1.43% | 13.9 | -65.2% |
| AMGN Amgen |
Biotechnology
Arthritis, Psoriasis |
159B | 73.8% | 68.7% | 16.3% | 24.2 | -23.9% |
| GILD Gilead Sciences |
Biotechnology
HIV,AIDS,Hepatitis,COVID,Cancer |
144B | 75.6% | 63.7% | 84.5% | 23.0 | 25.7% |
| VRTX Vertex |
Biotechnology
Cystic Fibrosis, Sickle Cell, Beta |
99.3B | 83.6% | - | 15.6% | 27.6 | -32.0% |
| REGN Regeneron |
Biotechnology
Injection, Antibody, Treatment |
63.4B | 79.9% | 1.0% | -29.8% | 15.1 | -58.8% |
| ALNY Alnylam |
Biotechnology
Therapeutics, RNA Interference |
59.1B | 35.3% | - | 74.0% | - | 36.9% |
| LONN Lonza |
Biotechnology
Biologics, SmallMolecules |
50.1B | 63.8% | 52.3% | 12.0% | 55.2 | -12.4% |
| HLN Haleon |
Biotechnology
OralHealth, Vitamins, PainRelief |
43.5B | 61.3% | 44.8% | 39.2% | 21.6 | -16.1% |
| ARGX argenx |
Biotechnology
Therapies, Treatments |
43.3B | 83.8% | - | 72.3% | 36.0 | 15.3% |
| ARGX Argen-X |
Biotechnology
Therapies, Treatments, Medicines |
43.0B | 81.3% | - | 61.8% | 35.7 | 10.7% |
| ONC BeiGene |
Biotechnology
Cancer Treatments, Oncology |
37.5B | 51.2% | - | 30.5% | - | 27.8% |
| INSM Insmed |
Biotechnology
Therapies, Treatments |
27.4B | 32.2% | - | 62.0% | - | 49.9% |
| BNTX BioNTech SE |
Biotechnology
Immunotherapies, Cancer |
27.3B | 19.2% | 1.0% | 0.18% | - | -1.80% |
| 22UA BioNTech SE |
Biotechnology
Immunotherapies, Cancer |
27.2B | 31.1% | 1.0% | -16.2% | - | -4.76% |
| NTRA Natera |
Biotechnology
Prenatal Tests, Genetic Screening |
22.0B | 47.3% | - | 53.0% | - | 20.1% |
| BIIB Biogen |
Biotechnology
Therapies, Multiple Sclerosis |
20.0B | 61.1% | - | -68.8% | 13.1 | -44.8% |
| SMMT Summit Therapeutics |
Biotechnology
Immunotherapy, Antibody, Cancer |
19.5B | 30.6% | - | 63.0% | - | 58.2% |
| BIM Biomerieux |
Biotechnology
Culture, PCR, AST, Sepsis, Software |
17.7B | 72.2% | 55.5% | 29.8% | 35.3 | -4.32% |
| INCY Incyte |
Biotechnology
Cancer Treatments, Blood |
16.9B | 73.7% | - | -9.50% | 20.5 | 8.36% |
| GMAB Genmab AS |
Biotechnology
Antibody, Cancer, Lymphoma |
14.7B | 79.4% | - | -39.5% | 12.3 | -23.0% |
| GMAB Genmab |
Biotechnology
Antibody, Cancer, Lymphoma, Cancer |
14.6B | 67.5% | - | -49.1% | 12.3 | -26.6% |
| ERF Eurofins |
Biotechnology
Testing, Laboratory, Services |
14.1B | 70.9% | 7.75% | 13.0% | 30.0 | 6.09% |
| UTHR United Therapeutics |
Biotechnology
Inhaled Solution, Injection |
14.0B | 90.8% | - | 27.5% | 12.1 | -27.5% |
| NBIX Neurocrine |
Biotechnology
Pharmaceuticals, Neurology |
13.6B | 79.0% | - | 23.7% | 40.5 | -4.60% |
| ASND Ascendis Pharma AS |
Biotechnology
Growth Hormone Therapy |
11.9B | 33.1% | - | 41.9% | - | 18.6% |
| BMRN Biomarin |
Biotechnology
Enzyme Replacement, Growth |
11.0B | 82.9% | - | -47.0% | 17.0 | -45.7% |
| MRNA Moderna |
Biotechnology
Vaccines, Therapeutics, RNA |
10.5B | 16.7% | - | -73.1% | - | -73.5% |
| EXEL Exelixis |
Biotechnology
Cabozantinib, Cobimetinib |
10.3B | 93.6% | - | 62.2% | 18.4 | 24.7% |
| BBIO BridgeBio Pharma |
Biotechnology
Attruby, Infigratinib, Encaleret |
9.81B | 46.7% | - | 47.4% | - | 79.4% |
| EXAS EXACT Sciences |
Biotechnology
Colon, Breast, Biomarker, Tumor |
8.54B | 44.7% | - | -52.5% | - | -34.8% |
| GRFS Grifols |
Biotechnology
Immunoglobulin, Albumin, Clotting |
8.41B | 63.9% | 29.3% | -22.9% | 19.3 | -5.26% |
| MDGL Madrigal |
Biotechnology
Rezdiffra, MASH, Thyroid, Agonist |
8.24B | 29.2% | - | 68.2% | - | 48.1% |
| ROIV Roivant Sciences |
Biotechnology
Antibody, Inhibitor, Activator |
8.06B | 22.9% | - | 4.78% | - | -15.5% |
| HALO Halozyme |
Biotechnology
Hyaluronidase Enzyme, Hylenex |
7.87B | 86.0% | - | 51.9% | 15.4 | -3.96% |
| ALK-B ALK-Abelló |
Biotechnology
Allergy Immunotherapy, Allergy |
7.01B | 64.8% | 17.3% | 40.2% | 45.2 | -4.43% |
| RVMD Revolution |
Biotechnology
Targeted Therapies, RAS |
6.81B | 21.0% | - | -14.9% | - | -23.6% |
| RYTM Rhythm |
Biotechnology
IMCIVREE, Obesity-Drug |
6.75B | 43.5% | - | 75.3% | - | 90.9% |
| IONS Ionis |
Biotechnology
Triglyceride,Neuromuscular,ADS,ATTR.. |
6.72B | 37.4% | 0.21% | -15.4% | - | -26.5% |
| LEGN Legend Biotech |
Biotechnology
CAR-T, BCMA, Gamma-Delta |
6.56B | 30.0% | - | -18.8% | - | -48.5% |
| AAPG Ascentage Pharma |
Biotechnology
Cancer Drugs, Hepatitis Therapy |
6.35B | 37.8% | - | 97.3% | - | 120% |
| RGC Regencell |
Biotechnology
TCM,Neurocognitive,ADHD,Autism,Herb.. |
6.21B | 26.6% | - | 67.7% | - | 6,060% |
| ABVX Abivax |
Biotechnology
Therapeutics, Obefazimod |
6.05B | 44.7% | - | 16.8% | - | 441% |
| RNA Avidity Biosciences |
Biotechnology
Antibody, Oligonucleotide |
5.66B | 25.9% | - | 12.3% | - | -5.38% |
| ABVX Abivax American |
Biotechnology
Hepatitis,HIV,Autoimmune,Infection |
5.62B | 27.7% | - | 41.6% | - | 466% |
| CRSP Crispr Therapeutics |
Biotechnology
Beta Thalassemia Therapy, Sickle |
5.43B | 29.7% | - | -25.9% | - | -5.06% |
| NUVL Nuvalent |
Biotechnology
ROS1 Inhibitor, ALK Inhibitor |
5.28B | 23.0% | - | 26.6% | - | -23.7% |
| MRUS Merus BV |
Biotechnology
Bispecific,Antibodies,Cancer,Clinic.. |
5.06B | 27.2% | - | 67.7% | - | 8.50% |
| ALKS Alkermes |
Biotechnology
Schizophrenia, Bipolar, Alcohol |
4.78B | 89.1% | - | 31.8% | 14.0 | -12.4% |
| ZEAL Zealand Pharma |
Biotechnology
Peptide Medicines, GLP-2 Analog |
4.60B | 59.6% | - | -5.44% | 4.50 | -56.4% |
| CYTK Cytokinetics |
Biotechnology
Omecamtiv, Aficamten, CK089, CK586 |
4.53B | 45.4% | - | -11.3% | - | -42.8% |
| TGTX TG Therapeutics |
Biotechnology
Briumvi, Ublituximab, TG-1701 |
4.46B | 61.6% | - | 28.8% | 73.9 | 5.39% |
| KRYS Krystal Biotech |
Biotechnology
VYJUVEK, Gene Therapies |
4.35B | 87.8% | - | 20.9% | 30.6 | -37.2% |
| PCVX Vaxcyte |
Biotechnology
Pneumonia Vaccine, Strep Vaccine |
4.17B | 17.2% | - | -34.3% | - | -66.7% |
| ADMA ADMA Biologics |
Biotechnology
Immune Globulin, Hepatitis B |
4.16B | 85.9% | - | 55.3% | 20.5 | -14.3% |
| ACAD ACADIA |
Biotechnology
Pimavanserin, Trofinetide |
4.14B | 63.5% | - | 12.1% | 18.4 | 42.0% |
| MTSR Metsera, Common |
Biotechnology
Injectable, Oral, Peptides |
4.12B | 29.5% | - | 76.6% | - | 80.4% |
| ACLX Arcellx |
Biotechnology
Anitocabtagene, ACLX-001 |
4.11B | 34.4% | - | 39.9% | - | -13.9% |
| PTCT PTC Therapeutics |
Biotechnology
Translarna, Emflaza, Upstaza |
3.94B | 83.3% | - | 24.1% | 7.03 | 20.2% |
| AKRO Akero Therapeutics |
Biotechnology
Efruxifermin, EFX, MASH Treatment |
3.84B | 24.8% | - | 49.2% | - | 49.8% |
| ZLAB Zai Lab |
Biotechnology
Zejula,Vyvgart,NUZYRA,Optune,Qinloc.. |
3.77B | 29.9% | - | -3.40% | - | 45.9% |
| SLNO Soleno Therapeutics |
Biotechnology
Diazoxide, Choline, Prader-Willi |
3.62B | 34.4% | - | 60.3% | - | 23.6% |
| PTGX Protagonist |
Biotechnology
Inject, Hepcidin, Mimetic |
3.50B | 65.6% | - | 58.5% | 77.0 | 15.6% |
| APLS Apellis |
Biotechnology
Empaveli, Syfovre, Geographical |
3.49B | 40.1% | - | -39.7% | - | -37.6% |
| MIRM Mirum |
Biotechnology
LIVMARLI, Cholbam, Chenodal |
3.47B | 44.3% | - | 80.2% | - | 46.3% |
| MLTX MoonLake |
Biotechnology
Sonelokimab, Tri-Specific |
3.45B | 25.2% | - | 54.7% | - | -0.52% |
| INDV Indivior Ordinary |
Biotechnology
Injection, Film, Tablet, Spray |
3.04B | 77.2% | 2.63% | 62.8% | 30.1 | 64.0% |
| LGND Ligand |
Biotechnology
Antiviral,Oncology,Vaccine,Respirat.. |
3.03B | 52.2% | 0.14% | 57.6% | - | 27.6% |
| SRRK Scholar Rock |
Biotechnology
Myostatin-Blocking Drug, Cancer |
3.03B | 27.5% | - | 37.2% | - | 213% |
| XENE Xenon |
Biotechnology
Seizure Drugs, Pain Drugs |
2.99B | 24.6% | - | 24.5% | - | -18.2% |
| KYMR Kymera Therapeutics |
Biotechnology
IRAK4 Program,STAT6 Program,TYK2 |
2.91B | 24.6% | - | -13.7% | - | -26.9% |
| BAVA Bavarian Nordic |
Biotechnology
Vaccines, Smallpox, Monkeypox |
2.91B | 71.0% | - | -22.0% | 14.2 | -24.3% |
| RARE Ultragenyx |
Biotechnology
Antibody,Biologic,Gene,Enzyme,Oligo |
2.86B | 38.3% | - | -78.5% | - | -55.5% |
| CRNX Crinetics |
Biotechnology
Paltusotine, Atumelnant, CRN09682 |
2.77B | 21.3% | - | -0.10% | - | -52.1% |
| NAMS NewAmsterdam |
Biotechnology
Cholesterol, Lowering, Medicine |
2.75B | 35.4% | - | 63.4% | - | 24.8% |
| ARWR Arrowhead |
Biotechnology
Arrowhead, siRNA, Therapy, Liver |
2.75B | 24.0% | - | -54.2% | - | -20.7% |
| VKTX Viking Therapeutics |
Biotechnology
Drugs, Liver, Diabetes, Obesity |
2.74B | 18.4% | - | 11.5% | - | -61.7% |
| IMVT Immunovant |
Biotechnology
Antibody, Graves, Arthritis |
2.66B | 21.0% | - | -51.8% | - | -59.8% |
| ALVO Alvotech |
Biotechnology
Biosimilar, Autoimmune, Eye, Bone |
2.63B | 56.3% | - | -32.2% | 36.2 | -41.3% |
| BIOA-B BioArctic (publ) |
Biotechnology
Biological Drugs, Antibodies |
2.57B | 37.5% | 0.21% | 66.7% | 27.2 | 63.9% |
| RXRX Recursion |
Biotechnology
Drug,Candidates,Pipeline |
2.51B | 25.2% | - | -72.0% | - | -43.9% |
| KNSA Kiniksa |
Biotechnology
Arcaxya, Mavripaxa, Sub):) |
2.49B | 56.9% | - | 52.2% | 671 | 7.95% |
| CPRX Catalyst |
Biotechnology
Firdapse, Fycompa, Ruzurgi, Agamree |
2.48B | 94.1% | - | 66.5% | 12.3 | -15.0% |
| IBRX Immunitybio |
Biotechnology
Vaccine Cancer, Cell Therapy |
2.41B | 50.2% | - | -71.5% | - | -51.2% |
| VCYT Veracyte |
Biotechnology
Cancer Biopsy Tests, Molecular |
2.38B | 59.4% | - | -32.4% | 88.4 | -19.5% |
| FOLD Amicus Therapeutics |
Biotechnology
Enzyme,Replacement,Therapy,Gaucher,.. |
2.35B | 46.6% | - | -59.5% | - | -42.0% |
| NNNN Anbio |
Biotechnology
Test, Kits, Devices, Reagents |
2.32B | 68.3% | - | 94.2% | 858 | 575% |
| APGE Apogee |
Biotechnology
Cystic Fibrosis,’Atopic |
2.28B | 29.7% | - | 14.2% | - | -35.8% |
| CNTA Centessa |
Biotechnology
Serpin, OXER1, Vasopressin |
2.28B | 31.3% | - | -4.05% | - | 4.39% |
| DNLI Denali Therapeutics |
Biotechnology
Alzheimer, Parkinson, ALS |
2.26B | 15.4% | - | -69.9% | - | -45.7% |
| AGIO Agios Pharm |
Biotechnology
Pyruvate Kinase Activator, IDH |
2.23B | 37.1% | - | -27.0% | 3.41 | -28.5% |
| BION BB Biotech |
Biotechnology
Portfolio,Fusion,Antibodies,Cell,Ca.. |
2.21B | 32.9% | 12.6% | -57.5% | - | -25.5% |
| GLPG Galapagos |
Biotechnology
Rheumatoid, Arthritis, Psoriatic |
2.17B | 21.5% | - | -44.6% | - | -8.38% |
| GLPG Galapagos |
Biotechnology
Filgotinib, Jyseleca, Crohns |
2.13B | 33.9% | - | -45.1% | - | -9.83% |
| IDYA Ideaya Biosciences |
Biotechnology
Cancer Drugs, Oncology Therapies |
2.13B | 17.8% | - | 3.20% | - | -46.5% |
| BLTE Belite Bio |
Biotechnology
Eye Drug, Eye Gene Therapy, Vision |
2.11B | 17.7% | - | 75.2% | - | 12.2% |
| CELC Celcuity |
Biotechnology
Cancer Test, Therapy Candidate |
2.10B | 23.8% | - | 45.2% | - | 180% |
| BONEX Bonesupport Holding |
Biotechnology
Injectable Bio-Ceramic, Bone |
2.06B | 87.4% | - | 44.1% | 134 | -9.59% |
| SRPT Sarepta |
Biotechnology
Gene Therapy, Antisense, Duchenne |
2.05B | 38.7% | - | -72.1% | - | -88.8% |
| MESO Mesoblast |
Biotechnology
Stem Cell Therapy, Regenerative |
2.05B | 27.1% | - | -4.35% | - | 113% |
| ARQT Arcutis |
Biotechnology
Topical Cream, Seborrheic |
2.03B | 32.8% | - | 4.10% | - | 23.1% |
| IRON Disc Medicine |
Biotechnology
Red, Blood, Iron, Drug, Clinical |
2.02B | 16.1% | - | -31.4% | - | 2.46% |
| DYN Dyne Therapeutics |
Biotechnology
Muscle, Oligonucleotide, Therapy |
1.96B | 23.6% | - | -50.4% | - | -74.0% |
| CGON CG Oncology |
Biotechnology
Cancer Immunotherapy Virus |
1.95B | 22.8% | - | -78.3% | - | -38.3% |
| VITR Vitrolife |
Biotechnology
Media, Pipettes, Lasers, Dishes |
1.92B | 55.6% | 41.2% | -63.8% | 40.4 | -47.6% |
| PROK ProKidney |
Biotechnology
Cell Therapy, Regenerative Medicine |
1.81B | 43.0% | - | -43.0% | - | -3.87% |
| VCEL Vericel Ord |
Biotechnology
Cartilage Repair, Burn Wound, Cell |
1.81B | 60.4% | - | 1.61% | 256 | -42.0% |
| BEAM Beam Therapeutics |
Biotechnology
Base Editing Platform |
1.80B | 22.5% | - | -55.1% | - | -45.0% |
| BCRX BioCryst |
Biotechnology
Oral Pill,Hereditary |
1.76B | 47.5% | - | 28.1% | - | -15.8% |
| VIMIAN Vimian |
Biotechnology
Diagnostics, Pharma, Veterinary |
1.72B | 61.3% | - | -59.4% | 68.3 | -34.9% |
| TWST Twist Bioscience |
Biotechnology
Synthetic Dna,Gene,Silicon Chips |
1.70B | 34.5% | - | -65.6% | - | -48.9% |
| COGT Cogent Biosciences |
Biotechnology
Kit, Bemarituzumab |
1.66B | 35.5% | - | -1.87% | - | -0.72% |
| IMCR Immunocore Holdings |
Biotechnology
Cancer Therapy, ImmTac, Melanoma |
1.63B | 45.4% | - | -13.6% | - | -24.2% |
| CLDX Celldex |
Biotechnology
Antibody, Vaccine, Cancer |
1.60B | 25.8% | - | -13.8% | - | -50.6% |
| AUPH Aurinia |
Biotechnology
Kidney Transplant Drug |
1.59B | 86.1% | - | 7.02% | 28.2 | 55.3% |
| NVAX Novavax |
Biotechnology
Vaccine, Covid, Nanoparticle |
1.58B | 56.5% | - | -78.3% | 4.37 | -42.1% |
| CDTX Cidara Therapeutics |
Biotechnology
Antifungals, Antivirals, Cancer |
1.56B | 16.8% | - | 27.3% | - | 328% |
| TVTX Travere |
Biotechnology
Kidney Drug, Rare Disease Therapy |
1.55B | 31.0% | - | -4.85% | - | 66.6% |
| BHVN Biohaven |
Biotechnology
Migraine Medicine, Neurology Drug |
1.55B | 36.4% | - | -0.73% | - | -67.8% |
| ARDX Ardelyx |
Biotechnology
Kidney Drug, Bowel Drug |
1.49B | 32.9% | - | -10.7% | - | -11.9% |
| PHVS Pharvaris BV |
Biotechnology
Bradykinin,Receptor,Antagonist,Drug.. |
1.49B | 21.7% | - | 0.68% | - | 8.06% |
| JANX Janux Therapeutics |
Biotechnology
T-Cell Redirectors, Prodrug Masks |
1.48B | 22.7% | - | -30.6% | - | -55.7% |
| VRDN Viridian |
Biotechnology
Antibody, Eye, Disease, Drug |
1.48B | 18.9% | - | -2.94% | - | 5.31% |
| EWTX Edgewise |
Biotechnology
Muscle, Disease, Drugs, Pipeline |
1.45B | 24.4% | - | -48.1% | - | -34.0% |
| VERA Vera Therapeutics |
Biotechnology
Kidney, Antibody, Protein, Disease |
1.37B | 17.7% | 3.50% | -4.10% | - | -48.4% |
| SNDX Syndax |
Biotechnology
Antibody, Kinase, Inhibitor |
1.36B | 25.5% | - | -35.3% | - | -32.9% |
| SPRY ARS |
Biotechnology
Cancer Antibody,Immune |
1.34B | 39.6% | - | -8.65% | - | -20.5% |
| ETNB 89bio |
Biotechnology
Experimental Therapy, Liver |
1.33B | 23.5% | - | -24.4% | - | -11.1% |
| ABCL Abcellera Biologics |
Biotechnology
Antibody, Discovery, Therapeutics |
1.28B | 15.4% | - | -31.7% | - | 42.7% |
| EVO Evotec SE |
Biotechnology
Drug Discovery, Therapeutics |
1.27B | 32.8% | - | -47.5% | - | -17.2% |
| GRAL GRAIL |
Biotechnology
Diagnostic, Screening, Cancer |
1.23B | 26.8% | - | 90.0% | - | 99.5% |
| 5CV CureVac |
Biotechnology
Mrna,Vaccines,Oncology,Therapeutics |
1.23B | 81.6% | - | -16.6% | 5.46 | 35.9% |
| DVAX Dynavax |
Biotechnology
Vaccine, Infectious Diseases |
1.23B | 36.0% | - | 6.76% | - | -20.7% |
| CVAC CureVac |
Biotechnology
mRNA Vaccines, mRNA Therapies |
1.22B | 81.7% | - | -16.5% | 5.35 | 42.2% |
| MNKD MannKind |
Biotechnology
Inhaled,Insulin,Diabetes,Respirator.. |
1.17B | 77.2% | - | 1.64% | 34.6 | -35.3% |
| OPK Opko Health |
Biotechnology
Diagnostics, Pharmaceuticals |
1.13B | 14.1% | - | -59.5% | - | -26.9% |
| RCUS Arcus Biosciences |
Biotechnology
Cancer, Immuno-Oncology |
1.11B | 26.8% | - | -70.0% | - | -47.8% |
| NTLA Intellia |
Biotechnology
CRISPR, Gene, Editing |
1.10B | 29.2% | - | -60.2% | - | -55.9% |
| PGEN Precigen |
Biotechnology
Gene Therapy, Cell Therapy |
1.08B | 29.1% | - | 11.4% | - | 242% |
| GPCR Structure |
Biotechnology
Small,Molecule,Drug,Candidates,Obes.. |
1.08B | 16.1% | - | -30.1% | - | -58.7% |
| ATNF 180 Life Sciences |
Biotechnology
Anti Tnf Therapy, Fibrosis |
1.08B | 48.7% | - | -59.3% | - | 25.7% |
| STOK Stoke Therapeutics |
Biotechnology
Antisense Oligonucleotides, Treat |
1.07B | 75.6% | - | -14.7% | 22.5 | 22.4% |
| ZYME Zymeworks Common |
Biotechnology
Bispecific Antibodies |
1.07B | 37.0% | - | -16.9% | - | 10.8% |
| LENZ LENZ Therapeutics |
Biotechnology
Presbyopia, Accommodative |
1.07B | 33.5% | 1.0% | -8.02% | - | 46.9% |
| MDXG MiMedx |
Biotechnology
Allograft, Wound, Graft, Membrane |
1.05B | 81.8% | - | 4.42% | 33.7 | -7.70% |
| ATAI ATAI Life Sciences |
Biotechnology
Psychedelics, Depression, Anxiety |
1.04B | 34.1% | - | -8.45% | - | 214% |
| SYRE Spyre Therapeutics |
Biotechnology
Monoclonal, Antibodies |
1.02B | 27.4% | - | -76.7% | - | -49.3% |
| BIOG-B BioGaia (publ) |
Biotechnology
Drops, Solutions, Tablets |
1.01B | 77.5% | 61.5% | -6.04% | 33.6 | -22.2% |
| PRAX Praxis Precision |
Biotechnology
Cns Therapies, Epilepsy Treatments |
991M | 31.5% | - | -61.7% | - | -23.5% |
| VALN Valneva SE |
Biotechnology
Japanese Encephalitis Vaccine |
990M | 11.4% | - | -26.1% | - | -0.90% |
| GUBRA Gubra |
Biotechnology
Peptides, CRO, Obesity, Fibrosis |
989M | 40.2% | 25.3% | 36.7% | - | -34.1% |
| MLYS Mineralys |
Biotechnology
Hypertension, Mineralocorticoid |
987M | 29.1% | - | 20.0% | - | 6.71% |
| PHARM Pharming |
Biotechnology
Protein Replacement Therapies |
986M | 47.4% | - | 29.5% | - | 49.8% |
| PHAR Pharming |
Biotechnology
RUCONEST, Joenja, OTL-105 |
957M | 48.8% | - | 22.3% | - | 66.0% |
| ORIC Oric |
Biotechnology
Androgen, Kinase, Precision |
946M | 27.9% | - | -30.1% | - | -16.2% |
| IOVA Iovance |
Biotechnology
Cell, Therapies, Interleukins |
941M | 35.3% | - | -86.7% | - | -83.3% |
| NUVB Nuvation Bio |
Biotechnology
Oncology Pipeline Drug Candidates |
921M | 30.9% | - | -56.4% | - | -24.1% |
| GERN Geron |
Biotechnology
telomerase, inhibitor, oncology |
919M | 37.0% | - | -40.4% | - | -73.1% |
| OCS Oculis Holding |
Biotechnology
Ophthalmology,Eye,Drugs,Therapy,Tre.. |
917M | 20.5% | - | 67.4% | - | 14.9% |
| SANA Sana Biotechnology |
Biotechnology
Engineered Cells, Cell Therapies |
909M | 39.5% | - | -63.5% | - | -56.3% |
| IMNM Immunome |
Biotechnology
Antibody, Oncology, Bispecific |
892M | 29.0% | - | -39.5% | - | -45.8% |
| URGN UroGen Pharma |
Biotechnology
Urothelial Cancer, Jelmyto, RTGel |
875M | 33.2% | - | -3.38% | - | 16.1% |
| QURE Uniqure |
Biotechnology
Gene Therapy, Hemophilia Treatment |
866M | 42.6% | - | -10.3% | - | 128% |
| TSHA Taysha Gene |
Biotechnology
Gene, Therapies, CNS, Diseases |
818M | 28.5% | - | -23.0% | - | 15.1% |
| AVBP ArriVent |
Biotechnology
Targeted Therapies, Kinase |
816M | 29.5% | - | -19.6% | - | -40.0% |
| AVXL Anavex Life |
Biotechnology
Alzheimers, Parkinsons |
807M | 29.6% | - | 41.0% | - | 33.2% |
| AKBA Akebia Ther |
Biotechnology
Kidney, Disease, Therapeutics |
806M | 28.8% | - | 5.66% | - | 73.8% |
| GHRS GH Research |
Biotechnology
Inhalable, Intravenous |
778M | 25.2% | - | 11.3% | - | 6.91% |
| VLA Valneva SE |
Biotechnology
Vaccine, Japanese Encephalitis |
778M | 23.8% | - | -5.49% | - | -0.30% |
| SION Sionna |
Biotechnology
CFTR,Cystic,COPD,Lungs,Genes |
769M | 22.8% | - | 62.9% | - | 32.7% |
| TNGX Tango Therapeutics |
Biotechnology
Precision, cancer, treatments |
753M | 21.3% | - | -38.5% | - | -48.9% |
| RIGL Rigel |
Biotechnology
Tavalisse, Rezlidhia, GAVRETO |
753M | 92.8% | - | 26.9% | 7.73 | 159% |
| GYRE Gyre Therapeutics |
Biotechnology
Anti-Fibrotic, Anti-Inflammatory |
743M | 52.5% | 1.0% | -44.0% | 409 | -46.6% |
| MNMD Mind Medicine |
Biotechnology
Phase 3 Anxiety, Phase 1 Autism |
740M | 20.2% | - | 28.3% | - | 41.7% |
| DNTH Dianthus |
Biotechnology
Monoclonal Antibodies, DNTH103 |
731M | 25.9% | - | -66.6% | - | -25.7% |
| NRIX Nurix Therapeutics |
Biotechnology
Cancer, Autoimmune, Inflammatory |
729M | 33.9% | - | -69.6% | - | -68.1% |
| BSLN Basilea |
Biotechnology
Antifungal, Antibiotic |
727M | 83.4% | 0.10% | 8.56% | 8.15 | -14.2% |
| DNA Ginkgo Bioworks |
Biotechnology
Cell Engineering, Biosecurity |
707M | 19.5% | - | -34.0% | - | 46.1% |
| IMTX Immatics |
Biotechnology
ACT, Bispecifics, T-Cell |
692M | 26.4% | - | -53.3% | - | -59.1% |
| DAWN Day One |
Biotechnology
Tovorafenib, Ipsen, DAY301, VRK1 |
691M | 25.8% | - | -79.9% | - | -54.0% |
| IDIA Idorsia |
Biotechnology
CNS, Cardiovascular |
676M | 46.8% | 0.16% | -30.5% | - | 4.97% |
| TYRA Tyra Biosciences |
Biotechnology
TYRA-300, TYRA-200, TYRA-430 |
674M | 22.6% | - | -54.0% | - | -50.7% |
| SECARE Swedencare publ |
Biotechnology
Supplements, Treats, Grooming |
655M | 51.9% | 57.8% | -15.7% | 95.2 | -15.3% |
| ABUS Arbutus Biopharma |
Biotechnology
RNAi Therapeutic, PD-L1 Inhibitor |
648M | 30.3% | - | -12.9% | - | -19.0% |
| KALV Kalvista |
Biotechnology
Oral Inhibitors, Plasma |
645M | 36.2% | - | 9.65% | - | -10.9% |
| SVA Sinovac Biotech |
Biotechnology
Vaccine, Hepatitis, Influenza |
642M | 30.8% | 1.0% | - | 6.66 | -15.0% |
| CDNA CareDx |
Biotechnology
Kidney, Heart, Transplant |
631M | 47.3% | - | -72.0% | 11.3 | -63.2% |
| KURA Kura Oncology |
Biotechnology
Ziftomenib, Tipifarnib, KO-2806 |
624M | 34.2% | - | -75.8% | - | -66.0% |
| MEDCL Medincell |
Biotechnology
Schizophrenia, Pain |
620M | 63.6% | - | 30.1% | - | -19.6% |
| BCAX Bicara |
Biotechnology
Bifunctional, Therapies, Solid |
618M | 13.0% | - | -86.4% | - | -43.7% |
| VIR Vir Biotechnology |
Biotechnology
Hepatitis, Influenza, Coronavirus |
617M | 23.7% | - | -80.8% | - | -48.2% |
| RZLT Rezolute |
Biotechnology
Monoclonal Antibody, Oral |
609M | 26.8% | - | -25.1% | - | 31.4% |
| MGTX MeiraGTx Holdings |
Biotechnology
Gene, Therapy, Ocular |
603M | 37.6% | - | -0.55% | - | 54.9% |
| TRML Tourmaline Bio |
Biotechnology
Monoclonal Antibody, Medicines |
592M | 20.6% | 1.0% | -37.0% | - | 11.2% |
| KROS Keros Therapeutics |
Biotechnology
Blood, Heart, Muscle, Cell |
590M | 52.5% | - | -63.1% | 45.4 | -71.2% |
| RLAY Relay Therapeutics |
Biotechnology
Precision, Oncology, Genetics |
586M | 31.4% | - | -84.2% | - | -54.1% |
| CSTL Castle Biosciences |
Biotechnology
Dermatologic, Cancer, Diagnostics |
583M | 60.8% | - | -62.1% | - | -30.4% |
| ORKA Oruka Therapeutics |
Biotechnology
Monoclonal, Antibodies, Psoriasis |
578M | 19.7% | 1.0% | -57.9% | - | -42.4% |
| PRME Prime Medicine |
Biotechnology
Gene Editing Technology, Prime |
578M | 35.8% | - | -67.7% | - | -30.7% |
| ORGO Organogenesis |
Biotechnology
Wound Grafts, Skin Substitutes |
568M | 28.3% | - | 20.2% | - | 48.5% |